Use of ACEI/ARB is a major concern for clinicians in treating COVID-19 patients with hypertension because of the potential effect of ACEI/ARB on increasing the expression of ACE2 (angiotensin-converting enzyme 2), the binding receptor and entry point of the SARS-COV-2. The gene discussed is ACE2; the disease is COVID-19.